Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 2/20 | 0.57 |
| ▸ | GSK3B | P49841 | 1/20 | 0.57 |
| ▸ | BACE1 | P56817 | 1/20 | 0.57 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.47 |
| ▸ | XDH | P47989 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | PARP1 | P09874 | 2/20 | 0.43 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.41 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | PDE3B | Q13370 | 5/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 5/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | BLM | P54132 | 3/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9361947 | 0.74 | ADORA1 (0.44) | TYMPGSK3BBACE1ADORA1KDM4E | |
| 7-Deazaxanthine SCHEMBL1460298 | 0.73 | TYMP (1.00) | TYMPGSK3BBACE1XDHKDM4E | |
| SCHEMBL486486 | 0.71 | PDE3B (0.39) | TYMPGSK3BBACE1ADORA1KDM4E | |
| SCHEMBL13671666 | 0.65 | SRC (0.44) | TYMPGSK3BBACE1XDHKDM4E | |
| SCHEMBL4721357 | 0.65 | XDH (0.57) | TYMPGSK3BBACE1XDHKDM4E | |
| SCHEMBL12235164 | 0.65 | TYMP (0.44) | TYMPGSK3BBACE1XDHKDM4E | |
| SCHEMBL19153170 | 0.64 | ADORA1 (0.47) | ADORA1XDHCA12CA9PDE3B | |
| SCHEMBL4297133 | 0.64 | CA12 (0.50) | ADORA1CA12CA9CRBNPDE3B | |
| Oxypurinol SCHEMBL39154 | 0.62 | XDH (1.00) | TYMPGSK3BBACE1XDHKDM4E | |
| Oxypurinol SCHEMBL9003893 | 0.61 | XDH (0.96) | TYMPGSK3BBACE1XDHKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4323066-A1 | MEK INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2024-02-21 | — | — | EP | disclosed |
| US-20220380362-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2022-12-01 | — | — | US | disclosed |
| WO-2022221866-A1 | MEK INHIBITORS AND USES THEREOF | Ikena Oncology, Inc. (US) | 2022-10-20 | — | — | WO | disclosed |
| CN-114605408-A | 5-hydroxy-1, 3-disubstituted phenyl pyrido [2,3-d ] pyrimidine compound and preparation method and application thereof | 沈阳药科大学 | 2022-06-10 | — | — | CN | disclosed |
| CN-114573581-A | 5-substituted amino-1, 3-disubstituted phenyl pyrido [2,3-d ] pyrimidine compound and preparation and application thereof | 沈阳药科大学 | 2022-06-03 | — | — | CN | disclosed |
| CN-114456166-A | 5-substituted amino-3-methylpyrido [2,3-d ] pyrimidine compound and preparation and application thereof | 沈阳药科大学 | 2022-05-10 | — | — | CN | disclosed |
| CN-109336884-B | Method for synthesizing trametinib key intermediate | 安庆奇创药业有限公司 | 2021-02-05 | — | — | CN | disclosed |
| US-20180273531-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | JAPAN TOBACCO INC. (JP) | 2018-09-27 | — | — | US | disclosed |
| EP-1894932-A1 | 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-d]pyrimidine derivatives and related compounds for the treatment of cancer | Japan Tobacco, Inc. (JP) | 2008-03-05 | — | — | EP | disclosed |
| EP-1761528-B1 | 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER | JAPAN TOBACCO INC (JP) | 2008-01-09 | — | — | EP | disclosed |
| EP-1761528-A1 | 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO[2,3-D]PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER | Japan Tobacco, Inc. (JP) | 2007-03-14 | — | — | EP | disclosed |
| WO-2005121142-A1 | 5-AMINO-2,4,7-TRIOXO-3,4,7,8-TETRAHYDRO-2H-PYRIDO’2,3-D! PYRIMIDINE DERIVATIVES AND RELATED COMPOUNDS FOR THE TREATMENT OF CANCER | JAPAN TOBACCO INC. (JP) | 2005-12-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220380362-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | TYMP 1/4885GSK3B 3207/4885BACE1 4124/4885 |
| US-20180273531-A1 | PYRIMIDINE COMPOUND AND MEDICAL USE THEREOF | TYMP, TYMS, DPYD | TYMP 1/4885GSK3B 3207/4885BACE1 4124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.